Why the study?
Can circulating plasma miR-208a serve as a biomarker for the clinical prognosis of the chronic indeterminate phase of Chagas disease?
Can circulating plasma miR-208a serve as a biomarker for the clinical prognosis of the chronic indeterminate phase of Chagas disease?
Plasma miR-208a is a potential biomarker for predicting the clinical prognosis and progression to chagasic cardiopathy in patients with the chronic indeterminate phase of Chagas disease.
This is the authors' abstract. We don't add key points for this paper.
infection. Our findings support that the chronic indeterminate phase is a progressive phase involved in the genesis of chagasic cardiopathy and point out the use of plasma levels of miR-208a as candidate biomarker in risk-prediction score for the clinical prognosis of Chagas disease.
Answers are grounded in this paper and cite their sources.
May support miR-208a integration into Chagas prognosis models; leaves open prospective validation before clinical adoption.
No takes yet. Share an insight, caveat, or question.
Linhares‐Lacerda et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: